Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewing-prevalent area

Head and Neck

Volumn 33, Issue 12, 2011, Pages 1758-1764

  Hsieh, Chia Hsun ^a   Chang, John W C ^a,b   Hsieh, Jia Juan ^a   Hsu, Todd ^a   Huang, Shiu Feng ^a,b,c   Liao, Chun Ta ^b   Wang, Hung Ming ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

epidermal growth factor receptor (EGFR); head and neck neoplasm; oral cavity; Q787Q mutation; squamous cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; MALE; MISSENSE MUTATION; MOUTH CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ARECA; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; FEMALE; HABITS; HUMANS; MALE; MASTICATION; MIDDLE AGED; MOUTH NEOPLASMS; MUTATION; MUTATION, MISSENSE; POINT MUTATION; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAIWAN;

EID: 81255187875     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21665     Document Type: Article

References (34)

1. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25: 2164-2170. (Pubitemid 46954638)
2. Pomerantz RG, Grandis JR,. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol 2004; 31: 734-743. (Pubitemid 39602679)
3. Pernas FG, Allen CT, Winters ME, et al. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin Cancer Res 2009; 15: 2361-2372.
4. Schwentner I, Witsch-Baumgartner M, Sprinzl GM, et al. Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck. Head Neck 2008; 30: 1040-1044.
5. Mendelsohn J, Baselga J,. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799. (Pubitemid 46606324)
6. Astsaturov I, Cohen RB, Harari P,. Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer. Expert Rev Anticancer Ther 2006; 6: 1179-1193. (Pubitemid 44575572)
7. Ciardiello F, Tortora G,. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174.
8. Karamouzis MV, Grandis JR, Argiris A,. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007; 298: 70-82. (Pubitemid 47026772)
9. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144. (Pubitemid 41058345)
10. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008; 26: 5589-5595.
11. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
12. Liang MT, Chen CC, Wang CP, Wang CC, Lin WD, Liu SA,. The association of lymph node volume with cervical metastatic lesions in head and neck cancer patients. Eur Arch Otorhinolaryngol 2009; 266: 883-887.
13. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578. (Pubitemid 43209104)
14. Langer CJ,. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer 2008; 112: 2635-2645. (Pubitemid 351969206)
15. Sartor CI,. Mechanisms of disease: radiosensitization by epidermal growth factor receptor inhibitors. Nat Clin Pract Oncol 2004; 1: 80-87. (Pubitemid 40823747)
16. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-2177. (Pubitemid 46954639)
17. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL,. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85. (Pubitemid 41095117)
18. Marur S, Forastiere AA,. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008; 83: 489-501. (Pubitemid 351536473)
19. Dobrossy L,. Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 2005; 24: 9-17. (Pubitemid 40584773)
20. Lemos-Gonzalez Y, Paez de la Cadena M, Rodriguez-Berrocal FJ, Rodriguez-Pineiro AM, Pallas E, Valverde D,. Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients. Tumour Biol 2007; 28: 273-279. (Pubitemid 350165833)
21. Cohen EE, Lingen MW, Martin LE, et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 2005; 11: 8105-8108. (Pubitemid 41698754)
22. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139. (Pubitemid 38637993)
23. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10: 8195-8203.
24. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24: 4170-4176. (Pubitemid 46622295)
25. Lee JW, Soung YH, Kim SY, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11: 2879-2882.
26. Na II, Kang HJ, Cho SY, et al. EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. Eur J Cancer 2007; 43: 520-526. (Pubitemid 46177596)
27. Huang SF, Chuang WY, Chen IH, Liao CT, Wang HM, Hsieh LL,. EGFR protein overexpression and mutation in areca quid-associated oral cavity squamous cell carcinoma in Taiwan. Head Neck 2009; 31: 1068-1077.
28. Hama T, Yuza Y, Saito Y, et al. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 2009; 14: 900-908.
29. Sheikh Ali MA, Gunduz M, Nagatsuka H, et al. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 2008; 99: 1589-1594.
30. Taguchi T, Tsukuda M, Imagawa-Ishiguro Y, Kato Y, Sano D,. Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib. Oncol Rep 2008; 19: 65-71. (Pubitemid 351176132)
31. Kaneko K, Kumekawa Y, Makino R, et al. EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Front Biosci 2010; 15: 65-72.
32. Chen YJ, Chang JT, Liao CT, et al. Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci 2008; 99: 1507-1514.
33. Department of Health, the Executive Yuan, R.O.C. December 2006: Cancer registry: annual report in Taiwan area [in Chinese]. 2007.
34. Freedman ND, Abnet CC, Leitzmann MF, Hollenbeck AR, Schatzkin A,. Prospective investigation of the cigarette smoking-head and neck cancer association by sex. Cancer 2007; 110: 1593-1601. (Pubitemid 47463075)